Shots:
- Merck & SciBrunch have entered into an exclusive global license agreement for SPR2015, with Merck receiving exclusive rights to develop, manufacture & commercialize SPR2015 worldwide
- As per the deal, SciBrunch will receive ~$400M upfront & payment associated with development, commercialization & other milestones across multiple indications, representing the total deal value of ~$2.13B
- SPR2015 is a preclinical molecular glue KRAS G12D (ON) inhibitor showing nanomolar antiproliferative activity across KRAS G12D-mutant cell lines, good selectivity over KRAS wild-type cells, & compelling monotx. antitumor efficacy in multiple in vivo CDX/PDX models
Ref: Businesswire | Image: Merck & SciBrunch | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
